It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Histone methylation is an important post-translational modification that plays a crucial role in regulating cellular functions, and its dysregulation is implicated in cancer and developmental defects. Therefore, systematic characterization of histone methylation is necessary to elucidate complex biological processes, identify biomarkers, and ultimately, enable drug discovery. Studying histone methylation relies on the use of antibodies, but these suffer from lot-to-lot variation, are costly, and cannot be used in live cells. Chromatin-modification reader domains are potential affinity reagents for methylated histones, but their application is limited by their modest affinities. We used phage display to identify key residues that greatly enhance the affinities of Cbx chromodomains for methylated histone marks and develop a general strategy for enhancing the affinity of chromodomains of the human Cbx protein family. Our strategy allows us to develop powerful probes for genome-wide binding analysis and live-cell imaging. Furthermore, we use optimized chromodomains to develop extremely potent CRISPR-based repressors for tailored gene silencing. Our results highlight the power of engineered chromodomains for analyzing protein interaction networks involving chromatin and represent a modular platform for efficient gene silencing.
Engineered chromodomains are promising probes to analyze histone methylation. Here the authors designed high-affinity chromodomains for enhanced genome-wide binding analysis, live-cell imaging and ultra-potent CRISPR-based gene repression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 The Anvil Institute, Kitchener, Canada; Louisiana State University, Department of Pathobiological Sciences, School of Veterinary Medicine, Baton Rouge, USA (GRID:grid.64337.35) (ISNI:0000 0001 0662 7451)
2 Ludwig-Maximilians-University, Division of Molecular Biology, Biomedical Center Munich, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); University of Zurich, Department of Molecular Mechanisms of Disease, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
3 The Anvil Institute, Kitchener, Canada (GRID:grid.7400.3); University of Waterloo, School of Pharmacy, Waterloo, Canada (GRID:grid.46078.3d) (ISNI:0000 0000 8644 1405)
4 The Anvil Institute, Kitchener, Canada (GRID:grid.46078.3d); University of Waterloo, School of Pharmacy, Waterloo, Canada (GRID:grid.46078.3d) (ISNI:0000 0000 8644 1405)
5 University of North Carolina at Chapel Hill, CB 3290, Department of Chemistry, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208)
6 The Anvil Institute, Kitchener, Canada (GRID:grid.10698.36)
7 University of North Carolina at Chapel Hill, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208)
8 University of Zurich, Department of Molecular Mechanisms of Disease, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Utrecht University, Division of Genome Biology and Epigenetics, Institute of Biodynamics and Biocomplexity, Department of Biology, Utrecht, The Netherlands (GRID:grid.5477.1) (ISNI:0000000120346234)
9 The Anvil Institute, Kitchener, Canada (GRID:grid.5477.1); University of Waterloo, School of Pharmacy, Waterloo, Canada (GRID:grid.46078.3d) (ISNI:0000 0000 8644 1405)